US EditionPublished • loading... • Updated
Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Parallel Bio's $21M in Series A will drive aim to cut $2B and 9 years from drug development
Cambridge-based biotechnology company Parallel Bio has closed a $21 million Series A funding round led by AIX Ventures. The company develops a drug testing platform that uses human organoid technology as an alternative to animal testing. The funding round included new investors Amplo and Salesforce CEO Marc Benioff, along with existing backers Metaplanet, Humba Ventures,… The post Parallel Bio’s $21M in Series A will drive aim to trim $2B and 9 …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
